A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study)-Reference-Cited by-同舟云学术

A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study)

Published:2016-12 Issue:4 Volume:15 Page:329-336
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Hazama Shoichi,Maeda Hiromichi,Iwamoto Shigeyoshi,Kim Ho Min,Takemoto Hiroyoshi,Kobayashi Kenji,Sakamoto Junichi,Nagata Naoki,Oba Koji,Mishima Hideyuki

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference37 articles.

1. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

2. CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer;Loree;Clin Colorectal Cancer,2014

3. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer;Ducreux;Int J Cancer,2011

4. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results;Cassidy;Br J Cancer,2011

5. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials;Arkenau;J Clin Oncol,2008

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer;ecancermedicalscience;2022-12-15

2. Effects of different administration strategies of cetuximab on remission rate, MMPs, miR-106b-5p, PCAT-1, and adverse reactions in patients with RAS wild-type CRC liver metastasis;World Chinese Journal of Digestology;2022-02-28

3. Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis;The Oncologist;2022-02-19

4. Severe interstitial pneumonia caused by cetuximab: a case report and review of the literature;Anti-Cancer Drugs;2021-07-12

5. Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial;Clinical Colorectal Cancer;2020-12